Renovaro (RENB) Competitors

Renovaro logo
$0.72 -0.02 (-2.67%)
Closing price 04:00 PM Eastern
Extended Trading
$0.72 0.00 (-0.06%)
As of 05:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

RENB vs. ORKA, MGTX, PRTC, MREO, AKBA, ALT, KALV, PROK, KROS, and SAGE

Should you be buying Renovaro stock or one of its competitors? The main competitors of Renovaro include Oruka Therapeutics (ORKA), MeiraGTx (MGTX), PureTech Health (PRTC), Mereo BioPharma Group (MREO), Akebia Therapeutics (AKBA), Altimmune (ALT), KalVista Pharmaceuticals (KALV), ProKidney (PROK), Keros Therapeutics (KROS), and Sage Therapeutics (SAGE). These companies are all part of the "pharmaceutical products" industry.

Renovaro vs.

Renovaro (NASDAQ:RENB) and Oruka Therapeutics (NASDAQ:ORKA) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, risk, media sentiment, profitability, community ranking, dividends, valuation, institutional ownership and earnings.

Oruka Therapeutics' return on equity of -24.96% beat Renovaro's return on equity.

Company Net Margins Return on Equity Return on Assets
RenovaroN/A -67.54% -52.89%
Oruka Therapeutics N/A -24.96%-21.22%

Oruka Therapeutics is trading at a lower price-to-earnings ratio than Renovaro, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
RenovaroN/AN/A-$80.65M-$0.96-0.75
Oruka TherapeuticsN/AN/A-$5.34M-$6.26-1.90

Renovaro has a beta of 0.63, meaning that its share price is 37% less volatile than the S&P 500. Comparatively, Oruka Therapeutics has a beta of 0.77, meaning that its share price is 23% less volatile than the S&P 500.

Oruka Therapeutics received 16 more outperform votes than Renovaro when rated by MarketBeat users.

CompanyUnderperformOutperform
RenovaroN/AN/A
Oruka TherapeuticsOutperform Votes
16
100.00%
Underperform Votes
No Votes

Oruka Therapeutics has a consensus target price of $39.86, indicating a potential upside of 235.78%. Given Oruka Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Oruka Therapeutics is more favorable than Renovaro.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Renovaro
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Oruka Therapeutics
0 Sell rating(s)
0 Hold rating(s)
7 Buy rating(s)
2 Strong Buy rating(s)
3.22

In the previous week, Oruka Therapeutics had 6 more articles in the media than Renovaro. MarketBeat recorded 6 mentions for Oruka Therapeutics and 0 mentions for Renovaro. Renovaro's average media sentiment score of 1.89 beat Oruka Therapeutics' score of 0.53 indicating that Renovaro is being referred to more favorably in the media.

Company Overall Sentiment
Renovaro Very Positive
Oruka Therapeutics Positive

71.4% of Renovaro shares are held by institutional investors. Comparatively, 56.4% of Oruka Therapeutics shares are held by institutional investors. 21.7% of Renovaro shares are held by insiders. Comparatively, 22.7% of Oruka Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Oruka Therapeutics beats Renovaro on 11 of the 15 factors compared between the two stocks.

Get Renovaro News Delivered to You Automatically

Sign up to receive the latest news and ratings for RENB and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

RENB vs. The Competition

MetricRenovaroPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$114.02M$6.89B$5.67B$9.04B
Dividend YieldN/A2.90%5.31%4.00%
P/E Ratio-0.759.6390.3619.28
Price / SalesN/A312.491,035.8379.86
Price / CashN/A75.4646.0938.87
Price / Book0.815.535.135.00
Net Income-$80.65M$123.50M$113.24M$222.75M
7 Day Performance-1.20%-4.00%-0.99%-0.57%
1 Month Performance-9.34%-1.51%4.19%3.00%
1 Year Performance-78.62%2.27%21.68%17.85%

Renovaro Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
RENB
Renovaro
0.9317 of 5 stars
$0.72
-2.7%
N/A-78.4%$114.02MN/A-0.7520Positive News
ORKA
Oruka Therapeutics
2.6331 of 5 stars
$13.70
+1.9%
$43.17
+215.1%
N/A$479.50MN/A-2.19N/AGap Up
MGTX
MeiraGTx
4.7119 of 5 stars
$6.13
-2.5%
$23.50
+283.4%
-2.0%$479.08M$13.93M-5.07300Positive News
PRTC
PureTech Health
2.5599 of 5 stars
$19.50
+2.1%
$45.00
+130.8%
-23.4%$466.83M$3.33M0.00100Positive News
MREO
Mereo BioPharma Group
2.8039 of 5 stars
$2.99
-0.7%
$7.83
+162.0%
-27.5%$463.89M$1M0.0040News Coverage
AKBA
Akebia Therapeutics
4.2116 of 5 stars
$2.12
-5.4%
$7.50
+253.8%
+28.0%$462.54M$194.62M-9.22430Analyst Upgrade
Short Interest ↓
Gap Down
ALT
Altimmune
2.4555 of 5 stars
$6.44
-3.0%
$20.83
+223.5%
-39.8%$458.05M$52,000.00-4.1550Short Interest ↓
Gap Down
KALV
KalVista Pharmaceuticals
4.7013 of 5 stars
$9.22
+3.5%
$23.80
+158.1%
-42.1%$455.65MN/A-2.53100Insider Trade
Short Interest ↓
News Coverage
PROK
ProKidney
1.9141 of 5 stars
$1.55
-6.1%
$4.50
+190.3%
+27.0%$452.07MN/A-2.823Positive News
KROS
Keros Therapeutics
3.4433 of 5 stars
$11.13
-2.4%
$52.56
+372.2%
-80.8%$450.84M$651,000.00-2.14100Short Interest ↑
Analyst Revision
SAGE
Sage Therapeutics
4.6145 of 5 stars
$7.26
+0.1%
$10.53
+45.0%
-69.6%$444.09M$86.46M-1.30690Earnings Report
Analyst Forecast
Short Interest ↓
News Coverage

Related Companies and Tools


This page (NASDAQ:RENB) was last updated on 2/12/2025 by MarketBeat.com Staff
From Our Partners